Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study

View ORCID ProfileLaura Matrajt, Elizabeth R. Brown, Dobromir Dimitrov, Holly Janes
doi: https://doi.org/10.1101/2021.11.10.21266139
Laura Matrajt
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laura Matrajt
  • For correspondence: laurama@fredhutch.org
Elizabeth R. Brown
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
2Department of Biostatistics, University of Washington, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dobromir Dimitrov
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
3Department of Applied Mathematics, University of Washington, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Holly Janes
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Despite the development of safe and effective vaccines, effective treatments for COVID-19 disease are still desperately needed. Several antiviral drugs have shown to be effective in reducing hospitalizations, and it is expected Despite the development of safe and effective vaccines, effective treatments for COVID-19 disease are still desperately needed. Several antiviral drugs have shown to be effective in reducing hospitalizations, and are to be widely available in the coming months. In the present work, we use an agent-based mathematical model to assess the potential population impact of the use of antiviral treatments in locations in four countries with different demographic structure and current levels of vaccination coverage: Kenya, Mexico, United States (US) and Belgium. For each location, we varied daily treatment initiation rate (DTIR) and antiviral effect in reducing transmission (AVT). Irrespective of location and AVT, widespread antiviral treatment of symptomatic adult infections (≥ 20% DTIR) prevented the majority of COVID-19 deaths, and recruiting 6% of all adult symptomatic infections daily reduced mortality by a third in all countries. Furthermore, we show that targeting antiviral treatment to the oldest age group (65 years old and older, DTIR of 20%) can prevent over 47% of deaths. Our results suggest that early antiviral treatment (within two days of symptoms) is needed to mitigate transmission, preventing 50% more infections compared to late treatment (started 3 to 5 days after symptoms onset). Our results highlight the synergistic effect of vaccination and antiviral treatment: as vaccination rate increased, antiviral treatment had a bigger impact on overall transmission. These results suggest that antiviral treatments can become a strategic tool that, in combination with vaccination, can significantly reduce COVID-19 hospitalizations and deaths and can help control SASRS-CoV-2 transmission.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Scientific Computing Infrastructure at Fred Hutch was funded by ORIP grant S10OD028685. HJ was supported by R56AI143418 and R01CA152089 from the National Institutes of Health. LM, DD and HJ were supported by UM1 AI068635 from the National Insti- tutes of Health. ERB was supported by the Infectious Diseases Clinical Research Consortium through the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, under award number UM1AI148684. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • New runs with lower coverage and under a viral transmission similar to the Omicron variant were added.

Data Availability

Code will be available upon publication.

https://github.com/lulelita/antivirals_covid19

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 07, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study
Laura Matrajt, Elizabeth R. Brown, Dobromir Dimitrov, Holly Janes
medRxiv 2021.11.10.21266139; doi: https://doi.org/10.1101/2021.11.10.21266139
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study
Laura Matrajt, Elizabeth R. Brown, Dobromir Dimitrov, Holly Janes
medRxiv 2021.11.10.21266139; doi: https://doi.org/10.1101/2021.11.10.21266139

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (238)
  • Allergy and Immunology (519)
  • Anesthesia (124)
  • Cardiovascular Medicine (1407)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (291)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (580)
  • Epidemiology (10264)
  • Forensic Medicine (6)
  • Gastroenterology (526)
  • Genetic and Genomic Medicine (2611)
  • Geriatric Medicine (253)
  • Health Economics (495)
  • Health Informatics (1727)
  • Health Policy (788)
  • Health Systems and Quality Improvement (669)
  • Hematology (266)
  • HIV/AIDS (563)
  • Infectious Diseases (except HIV/AIDS) (12066)
  • Intensive Care and Critical Care Medicine (647)
  • Medical Education (272)
  • Medical Ethics (83)
  • Nephrology (286)
  • Neurology (2448)
  • Nursing (143)
  • Nutrition (374)
  • Obstetrics and Gynecology (486)
  • Occupational and Environmental Health (565)
  • Oncology (1314)
  • Ophthalmology (397)
  • Orthopedics (145)
  • Otolaryngology (235)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (341)
  • Pediatrics (776)
  • Pharmacology and Therapeutics (328)
  • Primary Care Research (294)
  • Psychiatry and Clinical Psychology (2390)
  • Public and Global Health (4987)
  • Radiology and Imaging (892)
  • Rehabilitation Medicine and Physical Therapy (520)
  • Respiratory Medicine (680)
  • Rheumatology (307)
  • Sexual and Reproductive Health (253)
  • Sports Medicine (244)
  • Surgery (296)
  • Toxicology (45)
  • Transplantation (140)
  • Urology (108)